Mounjaro and IVF: the clinical picture before you start fertility treatment

What the guidance says about GLP-1 medicines and fertility treatment

The NHS England guidance on weight-management injections is unambiguous: tirzepatide and semaglutide are not recommended for use during pregnancy, breastfeeding, or when a person is trying to conceive. That recommendation extends directly to IVF. Because IVF cycles are designed to result in pregnancy, treatment with Mounjaro should be paused before the stimulation phase begins, and your prescriber needs to be part of that conversation, not just your fertility clinic.

A question our prescribers hear most weeks is whether it is safe to continue Mounjaro right up until an embryo transfer. The answer, based on current licensed guidance, is no. The exact wash-out period before attempting conception is not fixed in a single published number, so this must be confirmed individually with your prescriber and reproductive medicine team, taking into account your dose and your treatment history.

It is also worth knowing that tirzepatide carries a Black Triangle (▼) status with the MHRA, meaning it is under additional monitoring. For anyone planning IVF, that makes early and open communication with both your prescriber and your fertility consultant particularly important.

Why weight matters before IVF, and where Mounjaro fits in

There is a well-established relationship between BMI and IVF outcomes. Many NHS fertility services and private clinics set BMI thresholds (commonly BMI 30 or 35) before accepting patients for treatment or funding cycles. Elevated BMI is associated with reduced response to ovarian stimulation, higher anaesthetic risk, and lower live birth rates per transfer, though outcomes vary widely between individuals.

This is where medically supervised weight management can be genuinely relevant. Reaching a clinic's BMI threshold before starting IVF is a legitimate clinical goal, and for some people Mounjaro has been the tool that made that possible. The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported average body-weight reductions of around 20–21% at the 15mg dose over 72 weeks, reductions that, for some patients, would shift them from above a fertility clinic's threshold to below it.

The key point is sequencing. Mounjaro can be a reasonable part of the preparation for IVF; it is not something to be continued into the cycle itself. Planning that transition in advance, with enough time for an appropriate wash-out period, is the medically sensible approach. If you are thinking about costs and private treatment options during this planning period, our cost context page explains what private weight-management treatment typically involves.

Contraception, oral pill absorption, and the IVF preparation window

For people using the oral contraceptive pill (including those using it as part of IVF protocol priming) there is a specific and verified clinical point about Mounjaro. Because tirzepatide slows gastric emptying, it can reduce absorption of oral medicines, including the pill. NHS guidance states that anyone starting Mounjaro while using an oral contraceptive should add a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase.

This matters in an IVF context because some protocols use the pill to time the cycle, and a reduction in pill efficacy could complicate scheduling. Your fertility team should know you are taking or have recently taken Mounjaro, and if you are also living with a condition such as multiple sclerosis, our page covering Mounjaro and MS in the UK addresses how complex health backgrounds can affect prescribing decisions. If you are also taking HRT alongside weight management treatment, there is a separate page covering that interaction in detail.

It is also worth understanding that IVF medication (gonadotropins, progesterone, trigger injections) involves multiple injected and oral medicines. Your prescriber and fertility clinic should have a complete picture of everything you are taking before stimulation begins. Mounjaro is a prescription medicine; its use, timing and pausing decisions sit with clinicians, not with self-management.

What to do next if you are planning IVF

If you are currently using Mounjaro and are planning or approaching an IVF cycle, the practical steps are these. Tell your fertility consultant what you are taking. Tell your Mounjaro prescriber that you are planning IVF, and ask about the right time to pause. Do not stop any prescription medicine abruptly without that conversation first. If you are still in the weight-management phase and IVF is some months away, continue under clinical supervision and use that time to reach your target.

For a fuller picture of what tirzepatide involves as a treatment, our Mounjaro overview covers the mechanism, schedule and eligibility in one place. Some patients also ask about how weight-loss treatment interacts with other aspects of their health, and our page on Mounjaro and erectile dysfunction is one example of where those wider questions are addressed honestly. If you have questions about whether weight-loss treatment is right for your situation at all, the Mounjaro: yes or no page works through the decision factors honestly. And if you are ready to talk to a prescriber, you can check your eligibility through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.